trans-2-Hexenal

CAS No. 6728-26-3

trans-2-Hexenal( —— )

Catalog No. M21392 CAS No. 6728-26-3

Trans-2-hexenal is an αβ-unsaturated carbonyl compound protecting plants against harmful substances.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 37 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G 27 Get Quote

Biological Information

  • Product Name
    trans-2-Hexenal
  • Note
    Research use only, not for human use.
  • Brief Description
    Trans-2-hexenal is an αβ-unsaturated carbonyl compound protecting plants against harmful substances.
  • Description
    Trans-2-hexenal is an αβ-unsaturated carbonyl compound protecting plants against harmful substances.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6728-26-3
  • Formula Weight
    98.14
  • Molecular Formula
    C6H10O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (509.48 mM)
  • SMILES
    CCC\C=C\C=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Konidari CN et al. Determination of plasma urine and bovine serum albumin low-molecular-weight carbonyl levels by capillary gas chromatography with electron-capture and mass-selective detection.Anal Biochem. 2005 Mar 1;338(1):62-70.
molnova catalog
related products
  • Polygalasaponin F

    Polygalasaponin F has anti-neuroinflammatory activity, can inhibit the release of inflammatory cytokines TNF-α and NO induced by lipopolysaccharides (LPS) and reduce the expression of inducible nitric oxide synthases.

  • Lophine

    Lophine can be used in the synthesis of protein kinase inhibitors, calcium antagonists, strong Chemicalbook cardiac agents, and antitumor drugs.

  • Belantamab

    Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17).